Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

[1]  J. Dick,et al.  A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. , 2012, Blood.

[2]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[3]  M. Diederich,et al.  Epigenomics of leukemia : from mechanisms to therapeutic applications Review , 2009 .

[4]  H. Kohrt,et al.  Acute myeloid leukaemia in the elderly: a review , 2011, British journal of haematology.

[5]  B. Ponder,et al.  Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers , 2011, International journal of cancer.

[6]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[7]  W. Hiddemann,et al.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.

[8]  Shiv k. Sharma,et al.  (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.

[9]  J. Dick,et al.  Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development , 2010, Nature Immunology.

[10]  A. Mai,et al.  Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. , 2010, Journal of the American Chemical Society.

[11]  P. Cole,et al.  Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. , 2010, Journal of the American Chemical Society.

[12]  R. Schüle,et al.  Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.

[13]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[14]  S. Baylin,et al.  Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes , 2009, Clinical Cancer Research.

[15]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[16]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[17]  A. Zelent,et al.  Differentiation therapy of acute myeloid leukemia: past, present and future. , 2009, Current opinion in hematology.

[18]  M. Loh,et al.  A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. , 2009, Blood.

[19]  E. Li,et al.  The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation , 2009, Nature Genetics.

[20]  E. Lundberg,et al.  A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies* , 2008, Molecular & Cellular Proteomics.

[21]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[22]  M. Boix-Chornet,et al.  DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. , 2008, Blood.

[23]  W. Huber,et al.  Model-based variance-stabilizing transformation for Illumina microarray data , 2008, Nucleic acids research.

[24]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[25]  J. Dick,et al.  Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells. , 2007, Experimental hematology.

[26]  S. Baylin,et al.  Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes , 2007, Proceedings of the National Academy of Sciences.

[27]  J. Dick,et al.  Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment , 2006, Nature Immunology.

[28]  Min Gyu Lee,et al.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. , 2006, Chemistry & biology.

[29]  J. Dick,et al.  Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells , 2005, Leukemia.

[30]  Eric S. Lander,et al.  Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse , 2005, Cell.

[31]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[32]  A. Zelent,et al.  Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. , 2005, Blood.

[33]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[34]  G. Mufti,et al.  Antiapoptotic Microenvironment of Acute Myeloid Leukemia , 2004, The Journal of Immunology.

[35]  Lucia Altucci,et al.  The promise of retinoids to fight against cancer , 2001, Nature Reviews Cancer.

[36]  L. Altucci,et al.  Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL , 2001, Nature Medicine.

[37]  F. Behm,et al.  Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. , 2000, Blood.

[38]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[39]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[40]  J. Dick,et al.  Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. , 1992, Science.

[41]  C. Bloomfield,et al.  Induction of differentiation in blast cells and leukemia colony-forming cells from patients with acute myeloid leukemia. , 1990, Blood.

[42]  E. Freireich,et al.  HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. , 1988, Blood.

[43]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[45]  The two-sample Winsorized t , 1980 .